Aclarion Inc (NASDAQ: ACON) is a healthcare technology company that uses Magnetic Resonance Spectroscopy, proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians identify which spinal discs are causing chronic low back pain. Revenue is generated through Nociscan, a SaaS platform that analyzes MRS data noninvasively to distinguish between painful and non-painful discs ahead of spine surgery decisions. Nociscan is CE Marked as a Class I legacy device under the EU Medical Device Directive, with full MDR compliance required by December 31, 2028, and has been traded on Nasdaq under the symbol ACON since its IPO on April 21, 2022. The company targets the approximately $10 billion spent annually in the United States on spine fusion procedures, with additional commercial activity in the United Kingdom. As of December 31, 2025, there were approximately 213 holders of record of common stock.

Revenue model

SaaS platform fees from Nociscan, a software tool licensed to physicians and healthcare providers for per-case or subscription-based analysis of MRS imaging data used in spine surgery planning.

Products and services

Nociscan: a SaaS platform using Magnetic Resonance Spectroscopy and augmented intelligence to noninvasively identify painful spinal discs in patients with discogenic low back pain. CE Marked as a Class I legacy device under the EU MDD, subject to reclassification as Class II under MDR by December 31, 2028.

Customers and end markets

Physicians and healthcare providers treating chronic low back pain, primarily in the context of lumbar spine fusion surgery planning. End markets include the U.S. spine fusion procedure market (approximately $10 billion annually) and the UK spinal fusion devices segment.

Value-chain role

Healthcare technology intermediary: Aclarion operates as a Business Associate under HIPAA, receiving and processing patient health information from healthcare providers (Covered Entities) to deliver diagnostic decision-support outputs via its SaaS platform.

Geographic exposure

United States (primary commercial market) and United Kingdom. CE Marking covers EU markets with ongoing MDR compliance obligations. UK regulatory requirements apply separately following Brexit.

Source: SEC 10-K, filed 2026-03-18

Industry: Services-Medical Laboratories Peers: Scworx Corp CareView Communications Inc GRASSHOPPER STAFFING, INC. HTG MOLECULAR DIAGNOSTICS, INC